- CORRESPONDENCE
The pharmaceutical industry must embrace synthetic alternatives to horseshoe-crab blood
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
202,72 € per year
only 3,97 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 633, 286 (2024)
doi: https://doi.org/10.1038/d41586-024-02893-6
Competing Interests
T.C.’s lab has been supported by MilliporeSigma, Johnson & Johnson, Relay Therapeutics, Merck Sharp & Dohme, SPT Labtech, National Defense Medical Center, Shanghai University of Traditional Chinese Medicine, Ministry of Education Taiwan, and Entos, Inc.. T.C. has consulted for the University of Dundee Drug Discovery Unit, Scorpion Therapeutics, Relay Therapeutics, Amgen, Genentech, Janssen, Pfizer, Vertex, MilliporeSigma, the US Food & Drug Administration, Gilead, AbbVie, Corteva, Syngenta, Firmenich, Biogen, Bayer, UCB Biopharma, National Taiwan University, AstraZeneca, Grunenthal, and Iambic Therapeutics (previously known as Entos, Inc.). He holds equity in Scorpion Therapeutics and is a co-founder of and equity holder in Iambic Therapeutics.
